Pulmonary Fibrosis and Interstitial Lung Disease
We provide evaluation and treatment of patients with interstitial lung disease (ILD), sarcoidosis, and pulmonary fibrosis (including idiopathic pulmonary fibrosis). Our Lymphangioleiomyomatosis (LAM) Clinic is one of only 24 nationally, and we conduct clinical trials to help improve treatment and prevention of this rare disease. Our goal is to advance new and improved therapies to enable patients with ILD to live longer, healthier lives.
Other highlights include:
- One of the nation’s largest ILD centers; >1,500 clinic visits annually
- Multiple NIH-supported, investigator-initiated trials
- Industry-sponsored trials
- Member of the Pulmonary Fibrosis Foundation network